Novel therapies for multiple myeloma (MM) can target mechanism(s) in the host-MM bone marrow (BM) microenvironment mediating MM progression and chemoresistance. Our studies showed increased numbers of tumor-promoting, immunosuppressive and drug-resistant plasmacytoid dendritic cells (pDCs) in the MM BM microenvironment. pDC-MM cell interactions upregulate interleukin-3 (IL-3), which stimulates both pDC survival and MM cell growth. Since IL-3 R is highly expressed on pDCs in the MM BM milieu, we here targeted pDCs using a novel IL-3 R-targeted therapeutic SL-401. In both in vitro and in vivo models of MM in its BM milieu, SL-401 decreases viability of pDCs, blocks pDC-induced MM cell growth, and synergistically enhances anti-MM activity of bortezomib and pomalidomide. Besides promoting pDC survival and MM cell growth, IL-3 also mediates progression of osteolytic bone disease in MM. Osteoclast (OCL) progenitor cells express IL-3 R, and we show that SL-401 abrogates monocyte-derived OCL formation and bone resorption. Finally, we show that SL-401 also decreases the viability of IL-3 R-expressing cancer stem-like cells in MM. Overall, our study provides the preclinical basis for clinical trials of SL-401 to block pDC-induced MM cell growth, inhibit osteoclastogenesis and target MM stem-like cell subpopulations to improve patient outcome in MM.
INTRODUCTION
The bone marrow (BM) microenvironment enhances growth, survival, and drug resistance in multiple myeloma (MM) cells. 1, 2 We have shown that interactions of tumor cells with BM accessory cells (BM stromal cells, bone cells, myeloid cells, fibroblasts and immune cells) generates a conducive microenvironment for MM cells to survive, proliferate, evade cytotoxicity of drugs and escape immune responses. 1, 3, 4 For example, our prior studies demonstrated the functional significance of interactions between MM cells and plasmacytoid dendritic cells (pDCs) in MM pathogenesis. 5, 6 Specifically, our studies showed that MM BM pDCs exhibit reduced ability to trigger T-cell proliferation compared to normal pDCs, consistent with the hallmark immune deficiency in MM. [5] [6] [7] [8] Our data also showed that increased frequency of pDCs in MM patient BM vs normal BM; and that pDCs are more frequently localized in MM BM than normal BM. Our analysis of clinicallyannotated patient samples showed a direct correlation between pDC frequency and disease progression. Importantly, pDCs enhances MM cell growth, survival and drug-resistance. 5 pDCs are relatively resistant to both conventional and novel anti-MM therapies. 5 We showed that pDC-MM interactions enhance secretion of cytokines/chemokines, which mediates both pDC migration and homing to MM BM. 5 Finally, aberrant pDCs function in MM is evidenced not only in their interaction with MM cells, but also with immune effector T and NK cells. For example, MM BM pDCs confer T-cell and natural killer (NK) cell immune suppression in the MM BM milieu. 6 Taken together, our studies therefore provide the basis for development of novel therapies targeting dysfunctional pDCs in MM, both to inhibit MM cell growth and survival and to restore immune function.
Our prior studies demonstrated the role of interleukin 3-receptor (IL-3 R)-mediated signaling during pDC-MM interactions. Specifically, we found that pDC-MM cell interactions significantly increases IL-3 secretion; and importantly, that IL-3 both stimulate pDC survival 9 and MM cell growth. 10 Our and other prior studies showed that pDCs, including MM patient pDCs, highly express IL-3 R. 5, [11] [12] [13] These findings demonstrate functional significance of IL-3 R-mediated signaling during pDC-MM interactions, and provide the rationale for therapeutically targeting IL-3 R-positive pDCs in MM.
In the current study, we investigated depletion of dysfunctional pDCs as a potential novel therapy in MM. We utilized therapeutic agent SL-401 to target IL-3 R on MM pDCs. [13] [14] [15] SL-401 is a recombinant fusion protein composed of human IL-3 fused via a Met-His linker to the catalytic and translocation domains of a truncated diphtheria toxin (DT). The IL-3 domain of SL-401 binds to its cognate receptor (IL-3 R), at which time SL-401 is then internalized, leading to: cleavage of truncated DT from IL-3 within an endosome, translocation of the DT fragment to the cytosol; ADP ribosylation of elongation factor 2; inactivation of protein synthesis; and cell death.
14 Since SL-401 inhibits protein synthesis, it is able to trigger cell death in relatively dormant cells; moreover, it is not a substrate of P-glycoprotein and other drug efflux pumps that are associated with multi-drug resistance. Importantly, clinical activity and a favorable side effect profile of SL-401 has recently been observed in a multicenter Phase I/II trial in patients with advanced hematologic cancers, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), a malignancy of pDC origin. [14] [15] [16] [17] [18] [19] [20] [21] [22] Our in vitro and in vivo studies show that SL-401 inhibits MM cell growth and survival, inhibits osteoclastogenesis, and targets MM stem-like cells, providing the rationale for its clinical evaluation to improve patient outcome in MM.
MATERIALS AND METHODS

Cell culture
MM cell lines and PBMCs from normal healthy donors were cultured in RPMI-1640 medium supplemented with 10% FBS and antibiotics. Human recombinant IL-3 was purchased from Peprotech Inc (Rocky Hill, NJ, USA). CD3-PE; CD4-FITC or APC-Cy7; CD8-APC, CD123-PE/PE-Cy5/FITC; CD138-FITC/PE/APC; CD133-PE and CD27-Alexa-700 were obtained from BD Biosciences (San Jose, CA, USA). HLA-DR Violet Blue, CD303 (BDCA-2)-FITC, CD14-PE, and CD11c-APC were purchased from Miltenyi Biotec (Auburn, CA, USA); CD304-BV421 was obtained from Biolegend. All immunomagnetic separation kits were purchased from Miltenyi Biotec. Bortezomib, lenalidomide, SAHA, dexamethasone and pomalidomide were purchased from Selleck Chemicals, LLC (Houston, TX, USA).
pDCs and MM cells purification
All studies with MM patient samples were performed in accordance with IRB-approved protocols (Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA). Helsinki protocol was followed for obtaining informed consent from all patients. pDCs were isolated from both bone marrow (BM) and peripheral blood (PB) mononuclear cells (PBMCs) using CD304 (BDCA-4/Neuropilin-1) microbeads kit (Miltenyi Biotec), and the purity of pDCs (CD3 − , CD14 − , CD19 − , CD20 − , CD56 − , CD11c − , MHC-II/CD123/BDCA-2 + ) was confirmed, as previously described. 5 The raw data obtained from flow experiments was analyzed using FACS Diva (BD Biosciences) and FlowJO software (ver 7.6.5, Tree Star Inc, Ashland, OR, USA). MM patient cells were purified (495% purity) by CD138 + selection (CD138 Microbeads kit, Miltenyi Biotec Inc), as previously described. 5, 6 CD4 + T cells, CD8 + T cells and monocytes were purified using positive immunomagnetic separation techniques (Ab-Microbeads kits; Miltenyi Biotec).
Isolation of clonogenic MM side population (MM-SP)
MM-SPs were isolated from RPMI-8226 cells by flow cytometry-based Hoechst 33342 staining (5 μg/ml; Ho-33342, Thermo Fisher Scientific, Waltham, MA, USA), as previously described. 23 MM-SPs were identified based on the appearance of scatter shift in Ho-33342 Blue-versus-Red plot, and sorted on FACS Aria-UV flow cytometer (BD Biosciences) with a purity of~99%. For the quantitative analysis of CD123/IL-3Rα + population, MMSPs were stained with fluorophore-conjugated anti-CD123/IL-3Rα Abs and analyzed using FACS. In some studies, Vybrant DyeCycle Violet (DCV; Life Technologies Inc, Carlsbad, CA, USA), was used for MM-SPs analyses following the same protocol; 23 circumventing the UV excitation of Hoechst 33342 by utilizing a violet laser for DCV flow analysis.
Cell viability, proliferation, and apoptosis assays Cell viability and proliferation in MM cell lines, patient MM cells, and normal PBMCs were assessed by MTT or WST assay, as previously described. 24, 25 Apoptosis was assessed with Annexin V-FITC/Propidium iodide apoptosis detection kit (BD Biosciences, San Jose, CA, USA), followed by analysis using FACS Canto II. DNA synthesis was assessed using (3H) thymidine uptake (3H-Tdr) (PerkinElmer, Boston, MA, USA), as previously described. 5 Growth was also assessed by WST assay. For pDCs/MM cells coculture assays, pDCs and MM cells were cultured at 1:5 pDC/MM ratio.
Osteoclast differentiation and TRAP staining of Monocyte-derived Osteoclasts
Monocytes from PBMC or BMMCs were cultured in the presence of hu-RANKL (40 ng/ml) and hu-M-CSF (25 ng/ml) for 2-3 weeks in RPMI medium. Cells were stained using tartrate-resistant acid phosphatase (TRAP) using TRAP-staining kit (SIGMA, St Louis, MO, USA) for visualization by microscopy. TRAP activity was measured in supernatants at the end of the culture period using a colorimetric substrate included in the TRAPstaining kit (SIGMA). Specifically, supernatants (30 μl) and chromogenic substrate/tartrate-containing buffer (170 μl) were added to each well of a 96-well plate (in triplicate) and incubated at 37°C for 3 h. TRAP activity was quantified in OCL culture supernatants by absorbance reading at 540 nm. To measure osteoclast resorption, monocytes from PBMCs were cultured in the presence of hu-RANKL (40 ng/ml) and hu-M-CSF (25 ng/ml) for 3 weeks in RPMI medium on OsteoAssay plates, with bone particles at the bottom of the well. Resorbed surface area was analyzed by assessing pit formation. In brief, following multinucleated OCL formation, culture medium was aspirated and cells were washed twice with PBS. Ten percent bleach solution was then added to the wells for 5 min at room temperature followed by washing thrice with distilled water and drying at room temperature for 5 h. The wells were stained with 1% toluidine blue to increase contrast, and pit clusters were observed by microscopy. The images were captured and analyzed using NIH ImageJ software (National Institute of Health (NIH), Bethesda, MD, USA). The bone plus OCL cultures were also subjected to TRAP staining and TRAP activity in supernatants collected from OCL cultures, with or without bone chips, was assessed as described above. CD123/IL-3Rα and CD14 expression on OCL progenitor cells was assessed using FACS.
MM patient BM-derived osteoblast formation and assessment of mineralization
The osteoprogenitor cells (pre-OB) obtained after culturing MM patient BM adherent cells for 3-4 days were stimulated with ascorbic acid (0.05 mg/ ml), β-glycerophosphate (2.16 mg/ml) and 10 nM of dexamethasone for 3 weeks to obtain BM-derived osteoblasts (OBLs). The OBLs were cultured in the presence or absence of indicated concentrations of SL-401, followed by assessment of bone mineralization (calcium deposits) using Alizarin Red staining and Osteogenesis Assay kit (Catalog No. ECM810, Millipore, USA).
Transfection assays RPMI-8226 and MM-SP cells were transfected with a phOct4-GFP construct using the cell line Nucleofector Kit V (Amaxa Biosystems, Gaithersburg, MD, USA), followed by selection with G418 to derive stable RPMI-8226-Oct4 and MM-SP-Oct4 cell lines. Oct-4/GFP expression was confirmed using FACS. ), or MM.1 S plus pDCs 1:5 (pDC/MM) ratio in 100 μl of serum-free RPMI 1640 medium. When tumors were measurable (300 mm 3 ), mice (five mice per group) were administered with vehicle alone or SL-401 (16 μg/kg, IV) for 5 consecutive days each week for 2 weeks. Tumor growth was measured as previously described. 24 KaplanMeier plots were derived with GraphPad Prism (La Jolla, CA, USA). Human SCID-hu model: This model has been described previously. 27 INA-6 MM cells (2 × 10 6 cells), alone or together with pDCs (0.4 × 10 6 cells) at 1:5 (pDC: MM) ratio, were injected directly into the subcutaneously implanted human fetal bone in SCID-hu mice. Upon the first detection of soluble human IL-6 receptor (sIL-6R) in mouse serum, mice were treated with vehicle control or SL-401 (12 μg/kg; IV) for 5 consecutive days for 1 week. Mouse serum samples were analyzed at indicated times for human sIL-6 R (indicative of tumor burden) by ELISA.
Statistics
Student's t-test was applied to derive statistical significance. Mice survival was calculated with GraphPad Prism software. Cytotoxic activity of drug combinations was calculated using isobologram analysis and CalcuSyn software program.
RESULTS
Targeting pDCs and pDC-stimulated proliferation of MM cells with novel agent SL-401
Our earlier study showed that IL-3 R-mediated signaling during pDC-MM interactions mediates pDC survival and MM cell growth. pDCs have been reported to express high levels of IL-3 R;
11-13 here we also found that MM patient-derived pDCs (n = 6) exhibit high IL-3 R expression ( Figure 1a ; left and right panels; green color). Moreover, MM cells express IL-3 R as well, albeit at lower levels than pDCs ( Figure 1a , left and right panels; blue color). These data identify IL-3 R as a potential therapeutic target primarily on pDCs. In this context, recent research efforts led to the development of a novel therapeutic agent SL-401 ( Figure 1b , schematic of SL-401 construction) that specifically targets IL-3 R and IL-3 R-rich pDCs in particular, including the pDC-derived malignancy BPDCN. [13] [14] [15] We first examined the efficacy of SL-401 against pDCs and associated MM cell growth. Freshly purified pDCs and MM cells from patient BM were treated with increasing concentrations of SL-401 for 24 h, and then analyzed for apoptosis. Low picomolar concentrations of SL-401 were sufficient to induce apoptosis in pDCs (495%; IC 50 :~13 pM) (Figure 1c) . SL-401 also triggers a moderate apoptosis (30 ± 1.3% apoptosis at 1.36 nM) in MM cells, albeit at much higher concentrations (Figure 1c and supplementary Figure 1A , respectively). We next examined the effect of SL-401 on pDCs-induced growth of both MM cell lines and autologous patient MM cells. For pDC-MM co-culture studies, we utilized 1:5 (pDC/MM) ratio, which we established as a physiologically-relevant ratio in our previous study. 5 SL-401 blocked pDCs-triggered proliferation of MM cell lines (Figure 1d and Supplementary Figure S1B) , and patient MM cells (Figure 1e ) in a concentration-dependent manner. Importantly, many tumor samples analyzed were obtained from patients with MM refractory to bortezomib, dexamethasone, or lenalidomide. We also examined the effect of SL-401 on cells other than pDCs. As shown in Figure 1f , SL-401 does not significantly decrease the viability of monocytes, CD4 + T cells or CD8 + T cells from MM patients, or PBMCs from normal healthy donors; in contrast, even low concentrations of SL-401 significantly decreased viability of pDCs. These data suggest a favorable therapeutic index for SL-401. Moreover, the normal tissue expression profile of IL-3 R is restricted to certain myeloid progenitors, mature monocytes, eosinophils, basophils, mast cells and pDCs. Importantly, no myelosuppression was noted in previous Phase I/II and phase II trials with SL-401 in patients with BPDCN or relapsed/refractory AML, further supporting the clinical application of SL-401 with a favorable therapeutic index. [14] [15] [16] [17] [18] [19] [20] [21] [22] SL-401 inhibits pDC-induced human MM cell growth in vivo and prolongs survival in human MM xenograft models We first determined the maximum-tolerated dose and toxicity of SL-401. SCID mice were intravenously injected with control vehicle or SL-401 (12 μg/kg, 16 μg/kg, 25 μg/kg or 50 μg/kg) for 5 consecutive days each week for 3 weeks. SL-401 at 16 μg/kg doses were well tolerated, while higher doses resulted in body weight decrease and toxicity (Supplementary Figure S2) . We next examined the efficacy of SL-401 (12 μg/kg) in targeting pDCs and pDC-triggered MM cell growth in vivo using two distinct murine xenograft model of human MM. The SCID-hu model allows for determining the in vivo anti-MM activity of various drugs in the Depletion of dysfunctional pDCs as myeloma therapypresence of human BM milieu. 5, 27 Human fetal bone is subcutaneously implanted in mice, and human MM cells are then injected into the bone, followed by measurement of secreted soluble interleukin-6 receptor (human sIL-6 R) in mouse sera, which serves as tumor growth marker. As in our prior study, 5 we found significantly increased tumor growth in mice injected with pDCs and human MM INA-6 cells than in mice receiving INA-6 cells alone (Figure 2a) . Importantly, treatment of mice with SL-401 blocked pDC-induced tumor growth (Figure 2a) . Consistent with our in vitro data (Figure 1c) , SL-401 triggered modest anti-MM activity (Figure 2a ). Anti-pDC activity of SL-401 was confirmed using a subcutaneous model of human MM in SCID mice. Similar to our findings in the SCID-hu model, SL-401 inhibited pDCtriggered MM cell growth in subcutaneous MM xenografts as well (Figure 2b) . Moreover, survival of SL-401-treated mice was significantly prolonged (Figure 2c ). These data demonstrate efficacy of SL-401 in targeting pDCs in vivo at doses that are well tolerated.
SL-401 adds to the anti-MM activity of proteasome inhibitor and immunomodulatory drug pomalidomide On the basis of our findings, we hypothesized that combining SL-401 to target pDCs with agents directly targeting MM cells will allow for both depletion of tumor-promoting pDCs and enhanced killing of tumor cells. Moreover, our prior studies show that combinations will better target pDCs, which are resistant to anti-MM therapies, as well as confer resistance and promote MM cell growth. 5 For example, our earlier study showed that pDCs are relatively resistant to bortezomib and block bortezomib-induced MM cell cytotoxicity; 5 conversely, combination of SL-401 may restore bortezomib-sensitivity in MM cells. Indeed, we here found that low concentrations of SL-401 combined with bortezomib triggers synergistic anti-MM cytotoxicity (Supplementary Figure S3) . In an analogous manner, we examined the combination of SL-401 with second-generation immunomodulatory agent (IMiD) pomalidomide, 28 which is FDA approved to treat relapsed refractory MM. We reported earlier that pDCs are resistant to first generation IMiD lenalidomide; 5 however, the effect of pomalidomide on pDCs is unknown. Cytotoxicity analysis showed that MM patient pDCs are relatively resistant to pomalidomide treatment as well (Figure 3a) . These findings were confirmed using plasmacytoid dendritic 29 cell line CAL-1 (Figure 3b ). Similar to MM-pDCs, Cal-1 induces MM cell growth in co-culture model (Supplementary Figure S4) . Isobologram analysis showed that the combination of low concentrations of SL-401 with pomalidomide triggers synergistic anti-MM cytotoxicity (Figures 3c and d , and Supplementary Figures S5A-B) . We also evaluated the efficacy of combined SL-401 and pomalidomide in vivo using our SCIDhuman (SCID-hu) mouse model. Mice were treated with vehicle control, SL-401 (12 μg/kg; IV), pomalidomide (2.5 mg/kg; orally) or SL-401 plus pomalidomide for 2 weeks (SL-401: 5 consecutive days for first 1 week; pomalidomide: 4 consecutive days weekly for 2 weeks). Significant inhibition of tumor growth was observed in mice treated with SL-401 plus pomalidomide versus mice SL-401 inhibits osteoclast formation and bone resorption, as well as stabilizes osteoblast formation As noted above, pDC-MM interactions enhance IL-3 secretion, which in turn promotes both pDC survival and MM cell growth. IL-3 also contributes to progression of osteolytic bone disease in MM by stimulating osteoclast (OCL) formation 3, 4, [30] [31] [32] and inhibiting osteoblast differentiation. 31 Previous studies showed that OCL progenitor cells express IL-3 R; [30] [31] [32] consistent with these findings, we here demonstrate IL-3 R expression on OCL progenitor cells (Figure 4a ). We next examined whether SL-401 affects the OCL formation. Specifically, monocytes from MM patient PBMCs were cultured with hu-M-CSF and hu-RANKL for 2 weeks to promote OCL differentiation, in the presence or absence of SL-401. OCLs were analyzed for tartrate-resistant acid phosphatase (TRAP) staining. As seen in Figure 4b , SL-401 decreased TRAP + cells versus control cultures. Consistent with these data, supernatants from SL-401-treated OCLs cultures showed significantly decreased TRAP activity (Figure 4c ). Examination with OsteoAssay plates (dentine discs) similarly showed inhibitory activity of SL-401 against OCL-mediated bone resorption (Figures 4d and e) . These data suggest that SL-401 inhibits monocyte-derived OCL formation and bone resorption.
We also examined whether SL-401 affects osteoblast differentiation. For these studies, we utilized osteoprogenitor cells (pre-OB) obtained by culturing MM patient BM adherent cells for 3-4 days. These cells were stimulated with ascorbic acid/ β-glycerophosphate/dexamethasone for 3-4 weeks in the presence and absence of SL-401, followed by analysis for bone mineralization using Alizarin Red staining. SL-401 promotes BMderived osteoblast formation (Figure 4f ). Taken together, these findings support the clinical relevance of SL-401, since it may both block pDC-induced MM cell growth and abrogate osteolytic bone disease in MM.
SL-401 targets tumor-initiating stem-like cells in MM Our and other prior studies identified clonogenic MM side population cells (MM-SPs), which exhibit stem-cell like features and contribute to relapse of MM. 23, 33 Although we showed that lenalidomide decreases MM-SP fraction, 23 therapies targeting MM-SP cells are lacking. We here examined the effect of SL-401 on MM-SP cells since: (1) A recent study showed that IL-3 R serves as a leukemia stem cell marker that predicts minimum residual disease and relapse in acute myeloid leukemia; and importantly, SL-401 targets these cells; 34, 35 (2) MM patient BM has elevated IL-3 levels; 31 and (3) pDC-MM interactions significantly increase IL-3 Table. CI o1.0 indicates synergy. (e) INA-6 MM cells (2 × 10 6 cells), alone or together with pDCs (0.4 × 10 6 cells) at 1:5 (pDC/MM) ratio were injected directly into the human fetal bone implant in SCID-hu mice. Upon the first detection of human sIL-6R in mouse serum, mice (five mice per group) were treated with vehicle control, SL-401 (12 μg/kg; IV), pomalidomide (2.5 mg/kg; orally) or SL-401 plus pomalidomide for 2 weeks (SL-401: 5 consecutive days for first 1 week; pomalidomide: 4 consecutive days weekly for 2 weeks). Mouse sera samples were analyzed for human sIL-6R (indicative of tumor burden) using ELISA (mean ± s.d.; P o0.05; n = 2).
Depletion of dysfunctional pDCs as myeloma therapylevels, confirming an active IL-3/IL-3 R signaling axis in the MM BM milieu. MM-SPs were isolated from RPMI-8226 and Dox-40 MM cell line, as previously described, 23 and analyzed for IL-3 R expression. As shown in Figure 5 35 MM-SPs were also analyzed for additional MM cell lines (KMS-11, OPM2 and NCI-H929). MM-SPs derived from KMS-11, OPM2 and NCI-H929 MM cells also exhibited higher IL-3 R levels versus respective parental cells, and cytotoxicity assays showed a significant dose-dependent decrease of viable MM-SPs after SL-401 treatment (Supplementary Figures S6A-C ). These data demonstrate the ability of SL-401 to target MM-SPs.
To further examine the anti-cancer stem-like cell activity of SL-401, we stably transfected stem-cell transcription factor Oct-4 into RPMI-8226 MM cells and MM-SPs. Oct-4 mediates drugresistance and stem-like cell characteristics. 26 Specifically, RPMI-8226 and MM-SP cells were transfected with a phOct4-GFP construct 26 and selected with G418 to derive stable RPMI-8226-Oct4 and MM-SP-Oct4 cell lines (see Supplemntary Figure S7 ). Using these cell lines, we examined the following: (1) whether surface markers associated with stem cells (CD123/IL-3 Rα, CD133 and CD27) are increased in Oct-4-transfected cells and (2) whether Oct-4-transfected cells become more sensitive to SL-401 treatment. As expected, Oct-4 transfection led to increased expression of stem cell markers IL-3R, CD133 or CD27 versus parental RPMI-8226 cells or MM-SPs (Figures 6a-c) . Of note, cytotoxicity However, relapse of MM occurs in many patients, and delineation of the mechanisms in the BM milieu mediating tumor cell growth, survival and drug resistance, as well as immune suppression can identify and validate potential novel therapeutic targets. Our prior studies identified the role of increased numbers of plasmacytoid dendritic cells (pDCs) in the MM BM as novel mechanisms both promoting tumor and suppressing host immunity. 5 The present study builds upon our prior results, and preclinically validates a novel therapeutic SL-401 to target and transiently deplete dysfunctional pDCs in MM. SL-401 has shown promising results in a multicenter Phase I/II trial in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a malignancy derived from pDCs, with a favorable toxicity profile and we here examined its preclinical effects using our in vitro and in vivo models of MM in the BM microenvironment.
Using in vitro pDC-MM co-culture model and human MM xenografts, we show that SL-401 decreases viability of drugresistant pDCs, which express IL-3 R and blocks pDC-induced MM cell growth. We also examined whether SL-401 targets other IL-3 R-expressing cells besides pDCs. In this context, previous studies demonstrated that IL-3 R is restricted to certain myeloid progenitors, mature monocytes, eosinophils, basophils, mast cells and pDCs. 36 In our study, we found no significant effect of SL-401 on the viability of monocytes, B cells or total PBMCs. Although SL-401 would target normal pDCs, adverse immune effects or immunosuppression has not been observed in the clinical studies 14, 15 to date, likely due to the restoration of normal pDCs post-SL-401 treatment. Importantly, SL-401 has already demonstrated tolerability, clinical activity and a favorable safety profile without myelosuppression in clinical trials of patients with relapsed AML and BPDCN. [14] [15] [16] [17] [18] [19] [20] [21] [22] Together, these findings suggest a favorable therapeutic index for SL-401.
We utilized two distinct human MM xenograft models to show that administration of clinically-achievable doses of SL-401 target pDCs in vivo and reduce pDC-mediated tumor growth. Moreover, no significant toxicity was observed in SL-401-treated mice. Since pDCs are resistant to anti-MM agents bortezomib and pomalidomide and protect MM cells against their cytotoxic effects, we hypothesized that SL-401-mediated depletion of dysfunctional pDCs may restore tumor sensitivity to bortezomib-or pomalidomide. Indeed, our combination studies showed that SL-401 synergistically enhanced the anti-MM activity of both bortezomib and pomalidomide. A similar synergy between SL-401 and anticancer agent cytarabine has been reported in leukemia xenograft models. 37 Our findings therefore support clinical trials of SL-401 with bortezomib and/or pomalidomide, in relapsed MM.
We showed that pDC-MM interactions enhance IL-3 levels; and importantly, that IL-3/IL-3 R signaling plays a role in osteolytic bone disease. Here we found that SL-401 inhibits osteoclast formation, bone resorption, and promotes osteoblast formation. Our data therefore provide the first evidence for the antiosteolytic activity of SL-401, which may serve as novel therapeutic strategy to prevent MM-associated bone disease.
We also identified a significant number of clonogenic side population cells in MM (MM-SPs) with characteristic stem cell-like features, which also express IL-3 R. A previous study similarly showed overexpression of IL-3 R on leukemic cancer stem cells (CSCs). 38, 39 Importantly, our studies demonstrated that SL-401 decreased the viability of IL-3 R expressing MM-SPs. Due to the paucity of MM-SPs in BM mononuclear cells from patients or MM cell lines, we derived stable MM cell lines expressing Oct-4 transcription factor, which promotes stemness and chemoresistance. A significant increase in the expression of stem cell markers (IL-3 R, CD133 and CD27) was noted in Oct-4-transfected-versus non-transfected MM cells, which correlated with increased sensitivity of these cells to SL-401. A recent study also demonstrated anti-CSC activity of SL-401 in advanced CML. 40 Together, our data suggests that SL-401 may target tumor-initiating stemlike cells and thereby abrogate development of drug-resistance in MM.
In summary, we here show that SL-401: (1) decreases the viability of immunologically-defective and tumor-promoting pDCs; (2) blocks pDC-induced MM cell growth; (3) synergistically enhances the anti-MM activity of anti-MM agents bortezomib and pomalidomide; (4) inhibits OCL formation and bone resorption; (5) promotes osteoblast formation and (6) decreases viability of IL-3 R-expressing cancer stem-like cells in MM. These preclinical data provide the rationale for clinical trials of SL-401, alone and in combination with pomalidomide or bortezomib, to overcome pDC-mediated both drug-resistance and MM progression, prevent osteolytic bone disease, deplete tumor-initiating stem cell-like subpopulations and improve patient outcome in MM. A clinical trial of SL-401 in MM is currently ongoing (NCT02661022).
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